Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies

Posted by rob on February 18, 2012 under Uncategorized | Comments are off for this article

Conclusions  This is the first study to evaluate the combination of a CDK inhibitor and a TKI in humans. The combination of flavopiridol
and imatinib is tolerable and produces encouraging responses, including in some patients with imatinib-resistant disease.

Content Type Journal ArticleCategory Clinical Trial ReportPages 1-11DOI 10.1007/s00280-012-1839-5Authors
Prithviraj Bose, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USAEdward B. Perkins, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USAConnie Honeycut, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USAMartha D. Wellons, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, USATammy Stefan, Case Comprehensive Cancer Center, Ca…
More